Aurobindo Pharma announced its consolidated financial results for the second quarter ended September 30, 2026 (Q2FY27). The company reported a significant 23.9% year-over-year increase in revenue from operations, reaching INR 10,263 Cr. Net profit also saw a substantial rise of 32.5% YoY to INR 1,124 Cr. The company also highlighted key business segment performances and received final USFDA approvals for 12 products.
Aurobindo Pharma Announces Strong Q2 FY27 Financial Results
Aurobindo Pharma Limited has announced its consolidated financial results for the second quarter of the financial year 2027 (Q2FY27), ending September 30, 2026. The company demonstrated robust performance, with revenue from operations reaching INR 10,263 Cr, marking a significant 23.9% increase compared to the same period last year (Q2FY26). This growth was driven by strong performance across its various business segments.
Key Financial Highlights
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a healthy rise of 28.5% YoY, amounting to INR 2,156 Cr. The EBITDA margin stood at 21.0%. Profit Before Tax (PBT) before share of Profit/Loss of Joint Venture grew by 32.7% YoY to INR 1,691 Cr. Consequently, the Net Profit for the period surged by 32.5% YoY to INR 1,124 Cr. Earnings Per Share (EPS) stood at INR 19.57.
Operational Performance and Segment Breakdowns
The consolidated operational performance revealed significant growth in key geographies. Revenue from US Formulations increased by 25% YoY to INR 4,555 Cr. Europe Formulations revenue rose by 27% YoY to INR 3,161 Cr. Growth Markets Formulations reported a 16% YoY increase to INR 1,026 Cr, while ARV revenue stood at INR 359 Cr. Total Formulations revenue grew by 24.2% YoY to INR 9,102 Cr. The Active Pharmaceutical Ingredients (API) segment also performed well, with revenues increasing 21% YoY to INR 1,162 Cr.
USFDA Approvals and Strategic Updates
In a significant development, Aurobindo Pharma received final approval from the USFDA for 12 products. These include various formulations targeting cardiovascular, anti-infective, central nervous system, and other therapeutic areas. The company also highlighted strong free cash flows of USD 146 million during the quarter and maintained a strong net cash position of USD 189 million as of September 30, 2026.
Dividend Declaration
The Board of Directors has declared an interim dividend of ₹7.0 per share, reflecting the company’s confidence in its financial performance and commitment to shareholder value.
Earnings Call Details
Aurobindo Pharma will host an earnings call on November 5, 2026, at 8:30 AM IST to discuss the results and future outlook. Participants can join the call via Zoom after pre-registration.
Source: BSE
